ProShare Advisors LLC Has $143,000 Stake in MaxCyte, Inc. (NASDAQ:MXCT)

ProShare Advisors LLC increased its stake in MaxCyte, Inc. (NASDAQ:MXCT) by 32.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 34,462 shares of the company’s stock after purchasing an additional 8,481 shares during the period. ProShare Advisors LLC’s holdings in MaxCyte were worth $143,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC boosted its position in shares of MaxCyte by 123.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 7,564 shares of the company’s stock worth $31,000 after buying an additional 4,173 shares during the period. BNP Paribas Financial Markets bought a new position in shares of MaxCyte during the 4th quarter worth approximately $56,000. Prudential Financial Inc. acquired a new stake in shares of MaxCyte in the fourth quarter valued at approximately $65,000. Catalyst Funds Management Pty Ltd bought a new stake in shares of MaxCyte in the fourth quarter worth $74,000. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in MaxCyte by 10.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 22,366 shares of the company’s stock worth $93,000 after purchasing an additional 2,154 shares during the last quarter. Institutional investors own 68.81% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have commented on MXCT shares. Wall Street Zen cut shares of MaxCyte from a “hold” rating to a “sell” rating in a research report on Saturday. Stifel Nicolaus lowered their price target on MaxCyte from $11.00 to $9.00 and set a “buy” rating on the stock in a research report on Wednesday, March 12th. Finally, BTIG Research set a $6.00 price objective on MaxCyte and gave the company a “buy” rating in a report on Wednesday, March 12th.

MaxCyte Price Performance

MaxCyte stock opened at $2.26 on Tuesday. MaxCyte, Inc. has a fifty-two week low of $2.10 and a fifty-two week high of $5.26. The firm has a market capitalization of $240.28 million, a PE ratio of -6.65 and a beta of 1.38. The company’s 50-day moving average is $2.52 and its 200-day moving average is $3.47.

MaxCyte (NASDAQ:MXCT) last released its quarterly earnings data on Wednesday, May 7th. The company reported ($0.10) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.10). The company had revenue of $10.39 million during the quarter, compared to analysts’ expectations of $9.05 million. MaxCyte had a negative return on equity of 16.00% and a negative net margin of 78.36%. As a group, analysts expect that MaxCyte, Inc. will post -0.42 EPS for the current year.

MaxCyte Company Profile

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.